Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  British American Tobacco Plc    BATS   GB0002875804

BRITISH AMERICAN TOBACCO PLC

(BATS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

British American Tobacco : VUSE Premarket Tobacco Product Application filed for substantive review by the FDA

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/28/2019 | 04:21am EST

British American Tobacco'sU.S. subsidiary Reynolds American Inc. (RAI) has today announced that the recently-submitted Premarket Tobacco Product Application (PMTA) for VUSE vapour products has been filed by the Food and Drug Administration (FDA) for substantive scientific review, moving the application one step further through the review process.

"This is a first-of-its-kind application for VUSE products, and it puts VUSE one step closer to gaining a marketing order from the FDA", says RAI CEO Ricardo Oberlander.

"The FDA will now review our scientific justification and determine the appropriateness of VUSE e-cigarette products against the public health standard.

"For adult tobacco consumers seeking an alternative source of nicotine, having FDA oversight of e-cigarette products is an important step to ensure those alternatives meet strict regulatory scrutiny."

The FDA's scientific review of the VUSE application - which totals more than 150,000 pages of research and data - comes just over six weeks after its initial submission to the FDA. The FDA, per its earlier-issued guidance, considers the following issues, among others:

* Risks and benefits to the population as a whole, including both users and non-users of tobacco products;

* Whether people who currently use any tobacco product would be more or less likely to stop using such products if the proposed new tobacco product were available;

* Whether people who currently do not use any tobacco products would be more or less likely to begin using tobacco products if the new product were available; and

* The methods, facilities, and controls used to manufacture, process, and pack the new tobacco product.

Dr. James Figlar, Executive Vice President within the RAI Group, explained the science behind the application, stating that: "We compiled both the data and clinical information necessary for predicting the effect of continued marketing of VUSE products on the public health. We surveyed current tobacco users to understand product use behaviour and demographics, conducted behavioural studies of current and non-users of tobacco to gauge consumer understanding of risks and interest in product use, and performed statistical population modelling to project the effect on the population as a whole."

He continued: "We also conducted clinical studies that looked at the abuse potential of VUSE products, which included examining nicotine pharmacokinetics, as well as conducted several studies to examine the aerosol properties of the products and the temperature during use.

"While many of the results of our studies are confidential and proprietary, we believe that our application is complete and meets the regulatory requirements laid out in FDA's guidance, and we will work with the Agency to address any questions they may have about our products throughout the review process."

The next step in the review process is the FDA evaluation of the scientific information and data in the VUSE application. The FDA will also conduct inspections of manufacturing sites, as well as sites and entities involved in clinical and nonclinical studies, as part of this review process. Thereafter, the application may receive market clearance or denial, based on the FDA's evaluation of the application and evidence. Enquiries

Will Hill

+44 (0) 20 8439 2600

Investor Relations

Mike Nightingale / Rachael Brierley / John Harney

+44 (0) 20 7845 1180 / 1519 / 1263

.

(C) 2019 M2 COMMUNICATIONS, source M2 PressWIRE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRITISH AMERICAN TOBACCO P
01/03EUROPE : European shares fall on Middle East tensions; oil surge hits airline st..
RE
01/03LONDON STOCK EXCHANGE : Big oil, tobacco firms help FTSE 100 outshine Europe
RE
01/03UK tobacco shares rise on U.S. e-cigarette ban exemptions
RE
01/03BRITISH AMERICAN TOBACCO : British American Tobacco welcomes FDA guidance as a f..
AQ
01/03BRITISH AMERICAN TOBACCO : BAT Response to FDA Flavour Guidance
PU
01/03BATS : Reynolds Ready to Comply With New FDA Flavor Guidelines
DJ
01/02FDA Bars Fruit, Mint Flavors in Cartridge-Based E-Cigarettes--4th Update
DJ
01/02FDA Bars Fruit, Mint Flavors in Cartridge-Based E-Cigarettes--3rd Update
DJ
01/02FDA Bars Fruit, Mint Flavors in Cartridge-Based E-Cigarettes--2nd Update
DJ
2019LONDON STOCK EXCHANGE : Profit-taking, firm pound hit FTSE 100 at decade-end
RE
More news
Financials (GBP)
Sales 2019 25 696 M
EBIT 2019 11 073 M
Net income 2019 6 642 M
Debt 2019 42 730 M
Yield 2019 6,04%
P/E ratio 2019 11,7x
P/E ratio 2020 10,6x
EV / Sales2019 4,75x
EV / Sales2020 4,52x
Capitalization 79 256 M
Chart BRITISH AMERICAN TOBACCO PLC
Duration : Period :
British American Tobacco Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRITISH AMERICAN TOBACCO P
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 3 674,44  GBp
Last Close Price 34,67  GBp
Spread / Highest target 13 747%
Spread / Average Target 10 500%
Spread / Lowest Target 6 198%
EPS Revisions
Managers
NameTitle
Jack Marie Henry David Bowles Chief Executive Officer & Executive Director
Richard George William Burrows Chairman
Alan Davy Director-Operations
Tadeu Luiz Marroco Executive Director & Finance Director
Marina Fagundes Bellini Director-Digital & Information
Sector and Competitors
1st jan.Capitalization (M$)
BRITISH AMERICAN TOBACCO PLC7.16%103 457
PHILIP MORRIS INTERNATIONAL4.08%136 263
ALTRIA GROUP2.36%95 032
ITC LIMITED1.28%41 704
JAPAN TOBACCO INC.0.71%38 915
IMPERIAL BRANDS PLC8.80%24 923